Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

ERK and RAS inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ERK (15) Ras (11) Akt (1) AMPK (1) Annexin A (1) Antibiotic (1) Apoptosis (6) Atg8/LC3 (1) Autophagy (1) Bcl-2 Family (1) CDK (1) Cyclin G-associated Kinase (GAK) (1) FAK (1) Farnesyl Transferase (1) Ferroptosis (1) FLT3 (1) Glutathione S-transferase (1) HBV (1) HCV (1) HDAC (1) HSP (1) ICMT (1) Interleukin Related (1) JNK (1) Microtubule/Tubulin (1) MMP (1) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) PARP (1) Phosphatase (2) Phospholipase (1) PI3K (1) PKC (1) Raf (3) Reactive Oxygen Species (1) RET (1) Ribosomal S6 Kinase (RSK) (1) SHP2 (2) STAT (1) TNF Receptor (2) VEGFR (1)
By Research Areas:	Cancer (23) Infection (2) Inflammation/Immunology (7)

By Targets:

ERK (15)

Ras (11)

Akt (1)

AMPK (1)

Annexin A (1)

Antibiotic (1)

Apoptosis (6)

Atg8/LC3 (1)

Autophagy (1)

Bcl-2 Family (1)

CDK (1)

Cyclin G-associated Kinase (GAK) (1)

FAK (1)

Farnesyl Transferase (1)

Ferroptosis (1)

FLT3 (1)

Glutathione S-transferase (1)

HBV (1)

HCV (1)

HDAC (1)

HSP (1)

ICMT (1)

Interleukin Related (1)

JNK (1)

Microtubule/Tubulin (1)

MMP (1)

mTOR (1)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

PARP (1)

Phosphatase (2)

Phospholipase (1)

PI3K (1)

PKC (1)

Raf (3)

Reactive Oxygen Species (1)

RET (1)

Ribosomal S6 Kinase (RSK) (1)

SHP2 (2)

STAT (1)

TNF Receptor (2)

VEGFR (1)

By Research Areas:

Cancer (23)

Infection (2)

Inflammation/Immunology (7)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Ras ERK Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156002

LUNA18 Paluratide	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide KRAS and *ERK* inhibitor. LUNA18 phosphorylates *ERK* and AKT and decreases cell proliferation in *RAS*-mutated cancer cells. LUNA18 exhibits *RAS* signal inhibition and potent anti-cancer activities through inhibiting interaction between *RAS* and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

HY-107753

XRP44X	Ras	Inflammation/Immunology Cancer
XRP44X inhibits *Ras*-induced transcription activation with the IC₅₀ of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2 . XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules .

HY-136579

ASN007 4 Publications Verification ERK-IN-3	ERK	Cancer
ASN007 (ERK-IN-3) is a potent and orally active inhibitor of *ERK. ASN007 inhibits* *ERK1/2* with low single-digit nM IC₅₀ values. ASN007 can be used for the research of cancers driven by RAS mutations .

HY-136579A

ASN007 benzenesulfonate 4 Publications Verification ERK-IN-3 benzenesulfonate	ERK	Cancer
ASN007 (ERK-IN-3) benzenesulfonate is a potent and orally active inhibitor of *ERK. ASN007 benzenesulfonate inhibits* *ERK1/2* with low single-digit nM IC₅₀ values. ASN007 benzenesulfonate can be used for the research of cancers driven by RAS mutations .

HY-N1374

Magnolin 1 Publications Verification	ERK	Inflammation/Immunology
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of *ERK1* and *ERK2* with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-50846

SCH772984 Maximum Cited Publications 142 Publications Verification	ERK	Cancer
SCH772984 is a highly selective and ATP-competitive *ERK* inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or *RAS* mutations .

HY-162460

*ERK1/2 inhibitor* 10**	ERK	Cancer
ERK1/2 inhibitor 10 (Compound 36c) is a potent *ERK1* and *ERK2* inhibitor (IC₅₀: 0.11 and 0.08 nM respectively). ERK1/2 inhibitor 10 inhibits ERK1/2 and blocks the phosphorylation expression of their downstream substrates p90RSK and c-Myc. ERK1/2 inhibitor 10 induces cell apoptosis and incomplete autophagy-related cell death. ERK1/2 inhibitor 10 shows potent antitumor efficacy against triple-negative breast cancer and colorectal cancer models harboring BRAF and RAS mutations .

HY-124514

UC-857993	Ras ERK	Cancer
UC-857993 is a selective *SOS1-Ras* inhibitor (K_d=14.7 μM, His₆-SOS1_cat), suppressing catalytic activity. UC-857993 also inhibits *ERK* and *Ras* activation, suppresses the growth of mouse embryonic fibroblasts (MEFs) .

HY-N6674

Diazepinomicin ECO-4601; TLN-4601; BU 4664L	Ras Apoptosis	Cancer
Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models .

HY-N1374R

Magnolin (Standard)	ERK	Inflammation/Immunology
Magnolin (Standard) is the analytical standard of Magnolin. This product is intended for research and analytical applications. Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-149710

POP-3MB	ICMT ERK	Cancer
POP-3MB (compound 1b) is an ICMT inhibitor (IC₅₀: 2.5 μM). POP-3MB changes the subcellular localization of K-Ras and inhibits Ras activation. POP-3MB also inhibits Erk phosphorylation .

HY-164389

SML-10-70-1	Ras	Cancer
SML-10-70-1 is a ligand for *RAS, which covalently modifies the K-Ras* G12C mutant protein, and inhibits the phosphorylation of *ERK* and Akt. SML-10-70-1 inhibits the proliferation of cancer cells H23, H358 and A549 with IC₅₀ of 26.6-47.6 μM .

HY-101494

Temuterkib 25+ Cited Publications LY3214996	ERK	Cancer
Temuterkib (LY3214996) is a highly selective inhibitor of *ERK1* and *ERK2, with IC₅₀* of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

HY-157740

XSJ-10	HDAC	Cancer
XSJ-10 is a HDAC inhibitor containing a RAS/RAF protein interfering unit, with IC_{50_s} of 0.05 and 0.04 μM in PANC-1 cells and HT-29 cells. XSJ-10 can effectively induce the apoptosis of cancer cells and suppress the tumor by strongly inhibiting the RAS-RAF-MEK-ERK signaling pathway and the acetylation level of HDAC3 .

HY-122241

MT477	PKC	Cancer
MT477 is a potent protein kinase C (PKC) inhibitor. MT477 induces apoptosis and necrosis. MT477 decreases the protein expression of Ras-GTP, p-Erk1/2, p-Elk1. MT477 shows antitumor activity .

HY-141523

Vociprotafib RMC-4630; SHP2-IN-7	SHP2 Phosphatase	Cancer
Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the *RAS-RAF-MEK-ERK* signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice .

HY-156498

RMC-7977 2 Publications Verification	Ras ERK Raf Ribosomal S6 Kinase (RSK) AMPK Apoptosis PARP	Cancer
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (K_d = 195 nM) and KRAS (G12V) (K_d = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of *ERK, CRAF, and RSK, as well as increasing PARP* cleavage. This leads to tumor regression, reduces resistance in KRAS ^G12C cancer models, and demonstrates good tolerability across various RAS cancer models .

HY-120793

CMC2.24 TRB-N0224	Ras Apoptosis MMP	Inflammation/Immunology Cancer
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting *Ras* activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC₅₀s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis .

HY-170550

*KRAS G12C inhibitor* 69**	Ras ERK	Cancer
KRAS G12C inhibitor 69 (Compound K09) is the inhibitor for mutant RAS protein KRASG12C with an IC₅₀ of 4.36 nM. KRAS G12C inhibitor 69 inhibits the *ERK* phosphorylation in NCI-H358 and MIA-PACA-2 with an IC₅₀ of 12 nM and 7 nM. KRAS G12C inhibitor 69 inhibits the proliferation of cancer cell NCI-H358 and MIA-PACA-2 with IC₅₀ of 3.15 nM and 2.33 nM .

HY-169212

I194496	PI3K Annexin A ERK VEGFR STAT Raf FAK Akt Ras	Cancer
I194496 is a potent cystathionine γ-lyase (CSE) inhibitor, with an IC₅₀ of 0.79 mM. I194496 can inhibit the growth of human TNBC cells via the dual targeting PI3K/Akt and Ras/Raf/ERK pathway and suppress the metastasis of human TNBC cells via down-regulating Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways .

HY-N6796

Manumycin A 2 Publications Verification	Antibiotic Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3	Infection Inflammation/Immunology Cancer
Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the *Ras/Raf/ERK1/2* signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .

HY-111940

LUT014	Raf	Inflammation/Immunology
LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the *MAPK/ERK* signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .

HY-100388

SHP099 60+ Cited Publications	SHP2 Phosphatase	Cancer
SHP099 is an allosteric SHP2 inhibitor, with IC₅₀s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2 ^D61Y, SHP2E69K, SHP2 ^A72V, SHP2 ^E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC₅₀: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth .

HY-149539

PLM-101	FLT3 RET	Cancer
PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) .

HY-153346

Elironrasib 1 Publications Verification RMC-6291	Ras ERK Apoptosis	Cancer
Elironrasib is an orally active and covalent inhibitor of KRAS ^G12C(ON). Elironrasib forms a tri-complex within tumor cells between KRAS ^G12C(ON) and cyclophilin A (CypA). Thus, Elironrasib prevents KRAS ^G12C(ON) from signaling via steric blockade of RAS effector binding. Elironrasib inhibits *ERK* signaling and induced apoptosis in KRASG12C-mutant H358 cells. Elironrasib also inhibits the proliferation of KRAS ^G12C mutant cells with a median IC₅₀ of 0.11 nM .

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the *Ras/Raf/MEK/ERK* pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

Cat. No.	Product Name	Target	Research Area

HY-156002

LUNA18 Paluratide	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide KRAS and *ERK* inhibitor. LUNA18 phosphorylates *ERK* and AKT and decreases cell proliferation in *RAS*-mutated cancer cells. LUNA18 exhibits *RAS* signal inhibition and potent anti-cancer activities through inhibiting interaction between *RAS* and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

Magnolin 1 Publications Verification	Structural Classification Classification of Application Fields Magnoliaceae Source classification Lignans Magnolia Liliflora Desr. Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields	ERK
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of *ERK1* and *ERK2* with IC₅₀s of 87 nM and 16.5 nM, respectively.

Manumycin A 2 Publications Verification	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Antibiotic Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3
Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the *Ras/Raf/ERK1/2* signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .

Magnolin (Standard)	Structural Classification Magnoliaceae Source classification Lignans Magnolia Liliflora Desr. Phenylpropanoids Plants	ERK
Magnolin (Standard) is the analytical standard of Magnolin. This product is intended for research and analytical applications. Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC₅₀s of 87 nM and 16.5 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks